380 related articles for article (PubMed ID: 26874914)
41. Myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis: Ringing in a new future.
Nathan DI; Feld J; El Jamal SM; Mascarenhas J; Tremblay D
Leuk Res; 2022 Apr; 115():106820. PubMed ID: 35279478
[TBL] [Abstract][Full Text] [Related]
42. SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts.
Visconte V; Makishima H; Jankowska A; Szpurka H; Traina F; Jerez A; O'Keefe C; Rogers HJ; Sekeres MA; Maciejewski JP; Tiu RV
Leukemia; 2012 Mar; 26(3):542-5. PubMed ID: 21886174
[No Abstract] [Full Text] [Related]
43. Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms.
Brecqueville M; Rey J; Bertucci F; Coppin E; Finetti P; Carbuccia N; Cervera N; Gelsi-Boyer V; Arnoulet C; Gisserot O; Verrot D; Slama B; Vey N; Mozziconacci MJ; Birnbaum D; Murati A
Genes Chromosomes Cancer; 2012 Aug; 51(8):743-55. PubMed ID: 22489043
[TBL] [Abstract][Full Text] [Related]
44. Myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis with co-mutated JAK2 and SF3B1.
Reinig EF; He R
Blood; 2017 Feb; 129(5):656. PubMed ID: 28153838
[No Abstract] [Full Text] [Related]
45. SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations.
Meggendorfer M; Bacher U; Alpermann T; Haferlach C; Kern W; Gambacorti-Passerini C; Haferlach T; Schnittger S
Leukemia; 2013 Sep; 27(9):1852-60. PubMed ID: 23628959
[TBL] [Abstract][Full Text] [Related]
46. Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis.
Broseus J; Florensa L; Zipperer E; Schnittger S; Malcovati L; Richebourg S; Lippert E; Cermak J; Evans J; Mounier M; Raya JM; Bailly F; Gattermann N; Haferlach T; Garand R; Allou K; Besses C; Germing U; Haferlach C; Travaglino E; Luno E; Pinan MA; Arenillas L; Rozman M; Perez Sirvent ML; Favre B; Guy J; Alonso E; Ahwij N; Jerez A; Hermouet S; Maynadié M; Cazzola M; Girodon F
Haematologica; 2012 Jul; 97(7):1036-41. PubMed ID: 22532522
[TBL] [Abstract][Full Text] [Related]
47. JAK2/CALR/SF3B1 triple-mutated myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis evolving to myelofibrosis and SF3B1 single-mutated acute myeloid leukemia: Evidence of a pre-JAK2 clone.
Yasuda H; Morishita S; Mori Y; Tsukune Y; Inano T; Harada S; Komatsu N
Leuk Res; 2021 Jan; 100():106496. PubMed ID: 33373831
[No Abstract] [Full Text] [Related]
48. De novo acute myeloid leukemia with 20-29% blasts is less aggressive than acute myeloid leukemia with ≥30% blasts in older adults: a Bone Marrow Pathology Group study.
Hasserjian RP; Campigotto F; Klepeis V; Fu B; Wang SA; Bueso-Ramos C; Cascio MJ; Rogers HJ; Hsi ED; Soderquist C; Bagg A; Yan J; Ochs R; Orazi A; Moore F; Mahmoud A; George TI; Foucar K; Odem J; Booth C; Morice W; DeAngelo DJ; Steensma D; Stone RM; Neuberg D; Arber DA
Am J Hematol; 2014 Nov; 89(11):E193-9. PubMed ID: 25042343
[TBL] [Abstract][Full Text] [Related]
49. Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells.
Dolatshad H; Pellagatti A; Fernandez-Mercado M; Yip BH; Malcovati L; Attwood M; Przychodzen B; Sahgal N; Kanapin AA; Lockstone H; Scifo L; Vandenberghe P; Papaemmanuil E; Smith CW; Campbell PJ; Ogawa S; Maciejewski JP; Cazzola M; Savage KI; Boultwood J
Leukemia; 2015 May; 29(5):1092-103. PubMed ID: 25428262
[TBL] [Abstract][Full Text] [Related]
50. Deregulation of genes related to iron and mitochondrial metabolism in refractory anemia with ring sideroblasts.
del Rey M; Benito R; Fontanillo C; Campos-Laborie FJ; Janusz K; Velasco-Hernández T; Abáigar M; Hernández M; Cuello R; Borrego D; Martín-Zanca D; De Las Rivas J; Mills KI; Hernández-Rivas JM
PLoS One; 2015; 10(5):e0126555. PubMed ID: 25955609
[TBL] [Abstract][Full Text] [Related]
51. Refractory anemia with ring sideroblasts associated with marked thrombocytosis: a mixed group exhibiting a spectrum of morphologic findings.
Gurevich I; Luthra R; Konoplev SN; Yin CC; Medeiros LJ; Lin P
Am J Clin Pathol; 2011 Mar; 135(3):398-403. PubMed ID: 21350094
[TBL] [Abstract][Full Text] [Related]
52. Refractory anaemia with ring sideroblasts associated with marked thrombocytosis (RARS-T) and JAK2(V617F) mutation transformed to acute myeloid leukaemia with chromosomal evolution including monosomy 7.
Pich A; Godio L
Leuk Res; 2010 Feb; 34(2):e69-70. PubMed ID: 19744708
[No Abstract] [Full Text] [Related]
53. Clinical and genetic characteristics of congenital sideroblastic anemia: comparison with myelodysplastic syndrome with ring sideroblast (MDS-RS).
Ohba R; Furuyama K; Yoshida K; Fujiwara T; Fukuhara N; Onishi Y; Manabe A; Ito E; Ozawa K; Kojima S; Ogawa S; Harigae H
Ann Hematol; 2013 Jan; 92(1):1-9. PubMed ID: 22983749
[TBL] [Abstract][Full Text] [Related]
54. The prognostic impact of mutations in spliceosomal genes for myelodysplastic syndrome patients without ring sideroblasts.
Kang MG; Kim HR; Seo BY; Lee JH; Choi SY; Kim SH; Shin JH; Suh SP; Ahn JS; Shin MG
BMC Cancer; 2015 Jun; 15():484. PubMed ID: 26115659
[TBL] [Abstract][Full Text] [Related]
55. Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a Mayo Clinic-French Consortium Study.
Wassie EA; Itzykson R; Lasho TL; Kosmider O; Finke CM; Hanson CA; Ketterling RP; Solary E; Tefferi A; Patnaik MM
Am J Hematol; 2014 Dec; 89(12):1111-5. PubMed ID: 25195656
[TBL] [Abstract][Full Text] [Related]
56. Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia.
Patnaik MM; Barraco D; Lasho TL; Finke CM; Reichard K; Hoversten KP; Ketterling RP; Gangat N; Tefferi A
Am J Hematol; 2017 Jun; 92(6):542-548. PubMed ID: 28314085
[TBL] [Abstract][Full Text] [Related]
57. Distinct iron architecture in SF3B1-mutant myelodysplastic syndrome patients is linked to an SLC25A37 splice variant with a retained intron.
Visconte V; Avishai N; Mahfouz R; Tabarroki A; Cowen J; Sharghi-Moshtaghin R; Hitomi M; Rogers HJ; Hasrouni E; Phillips J; Sekeres MA; Heuer AH; Saunthararajah Y; Barnard J; Tiu RV
Leukemia; 2015 Jan; 29(1):188-95. PubMed ID: 24854990
[TBL] [Abstract][Full Text] [Related]
58. Predicting survival in patients with myelodysplastic/myeloproliferative neoplasms with SF3B1 mutation and thrombocytosis.
Li F; Qin T; Li B; Qu S; Pan L; Zhang P; Sun Q; Cai W; Gao Q; Jiao M; Li J; Ai X; Ma J; Gale RP; Xu Z; Xiao Z
Leukemia; 2024 Jun; 38(6):1334-1341. PubMed ID: 38714876
[TBL] [Abstract][Full Text] [Related]
59. [Gene mutation and myelodysplastic syndromes with ring sideroblast excess].
Meng FK; Huang LF; Zhou JF; Sun HY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Aug; 21(4):1088-90. PubMed ID: 23998618
[TBL] [Abstract][Full Text] [Related]
60. Diagnosis and treatment of sideroblastic anemias: from defective heme synthesis to abnormal RNA splicing.
Cazzola M; Malcovati L
Hematology Am Soc Hematol Educ Program; 2015; 2015():19-25. PubMed ID: 26637696
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]